title: Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients.
abstract: OBJECTIVE
  To report the treatment efficacy and toxicity profile of intensitymodulated radiation therapy in Chinese patients with clinically localised prostate cancer.
  
  
  METHODS
  Historical cohort study.
  
  
  METHODS
  Oncology unit in a university teaching hospital in Hong Kong.
  
  
  METHODS
  Patients with clinically localised prostate cancer undergoing intensity-modulated radiation therapy in our institution between May 2001 and November 2009 were reviewed.
  
  
  METHODS
  The 5-year biochemical failure–free survival, 5-year overall survival, as well as acute/late gastro-intestinal toxicities and genito-urinary toxicities.
  
  
  RESULTS
  A total of 182 patients were treated with prostate intensitymodulated radiation therapy with or without whole-pelvic radiotherapy. The median follow-up was 44 months. The median patient age was 72 years. Overall survival of the cohort was 92% after 5 years. The favourable, intermediate, and unfavourable risk category distributions of the National Comprehensive Cancer Network were 21 (12%), 42 (23%), and 119 (65%), respectively. The 5-year actuarial biochemical failure–free survival rates for patients in these categories were 95%, 82%, and 80%, respectively. Multivariate analysis identified early tumour stage, low pre-treatment prostate-specific antigen levels, and the use of adjuvant androgen deprivation as independent prognostic factors for better biochemical failure–free survival. Grade 2 and 3 late gastro-intestinal/genito-urinary toxicities occurred in 8%/3% and 4%/3% of the patients, respectively.
  
  
  CONCLUSIONS
  Intensity-modulated radiation therapy for prostate cancer is feasible and safe in the Chinese population. These data are consistent with the results of other series in Caucasian populations.
authors.forename: D M C
authors.initials: DM
authors.lastname: Poon
authors.forename: S L
authors.initials: SL
authors.lastname: Chan
authors.forename: C M
authors.initials: CM
authors.lastname: Leung
authors.forename: K M
authors.initials: KM
authors.lastname: Lee
authors.forename: M K M
authors.initials: MK
authors.lastname: Kam
authors.forename: B K H
authors.initials: BK
authors.lastname: Yu
authors.forename: A T C
authors.initials: AT
authors.lastname: Chan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000209:etiology; D006723:Hong Kong; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014566:Urogenital System / Q000528:radiation effects
chemical_list: D017430:Prostate-Specific Antigen